Sarepta Therapeutics Inc.

104.90
-3.05 (-2.83%)
At close: Feb 18, 2025, 3:59 PM
105.35
0.43%
After-hours: Feb 18, 2025, 04:41 PM EST
undefined%
Bid 105
Market Cap 10.02B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 1.54
PE Ratio (ttm) 68.12
Forward PE n/a
Analyst Buy
Ask 106.77
Volume 987,080
Avg. Volume (20D) 868,438
Open 102.60
Previous Close 107.95
Day's Range 101.15 - 106.10
52-Week Range 101.15 - 173.25
Beta undefined

About SRPT

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 4, 1997
Employees 1,314
Stock Exchange NASDAQ
Ticker Symbol SRPT
Full Company Profile

Analyst Forecast

According to 21 analyst ratings, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $181, which is an increase of 72.55% from the latest price.

Buy 90.48%
Hold 4.76%
Sell 4.76%
Stock Forecasts

Next Earnings Release

Sarepta Therapeutics Inc. is scheduled to release its earnings on Feb 26, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+13.82%
Sarepta Therapeutics shares are trading higher aft... Unlock content with Pro Subscription
3 months ago
+2.37%
Sarepta Therapeutics shares are trading lower. The company reported Q3 financial results.